Squarepoint Ops LLC Cure Vac N.V. Transaction History

Squarepoint Ops LLC

$62.8 Billion
Q3 2024

A detailed history of Squarepoint Ops LLC transactions in Cure Vac N.V. stock. As of the latest transaction made, Squarepoint Ops LLC holds 39,165 shares of CVAC stock, worth $124,153. This represents 0.0% of its overall portfolio holdings.

Number of Shares

39,165

Holding current value

$124,153

% of portfolio

0.0%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$2.74 - $3.79 $107,312 - $148,435	39,165 New	39,165 $115,000
Q1 2024 May 15, 2024	BUY	$2.94 - $4.34 $30,617 - $45,196	10,414 New	10,414 $31,000
Q3 2022 Nov 14, 2022	SELL	$7.48 - $15.24 $268,576 - $547,207	-35,906 Reduced 56.73%	27,387 $216,000
Q2 2022 Aug 15, 2022	BUY	$13.18 - $19.41 $834,201 - $1.23 Million	63,293 New	63,293 $861,000
Q4 2021 Feb 14, 2022	SELL	$33.72 - $48.22 $229,296 - $327,896	-6,800 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$49.26 - $74.5 $119,209 - $180,290	-2,420 Reduced 26.25%	6,800 $371,000
Q2 2021 Aug 16, 2021	BUY	$56.91 - $127.53 $135,275 - $303,138	2,377 Added 34.74%	9,220 $677,000
Q1 2021 May 17, 2021	BUY	$79.79 - $126.29 $546,002 - $864,202	6,843 New	6,843 $626,000

Others Institutions Holding CVAC

# of Institutions

Shares Held

12.3M

Call Options Held

164K

Put Options Held

117K

Israel Englander Millennium Management LLC | New York, Ny

2.42M
Shares

$7.67 Million
0.0% of portfolio
Black Rock Inc. New York, NY

2.25M
Shares

$7.14 Million
0.0% of portfolio
Bill & Melinda Gates Foundation Seattle, WA

1.57M
Shares

$4.97 Million
10.6% of portfolio
Ken Griffin Citadel Advisors LLC | Chicago, Il

1.01M
Shares

$3.21 Million
0.0% of portfolio
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct

780K
Shares

$2.47 Million
0.01% of portfolio

View Full List

About CureVac N.V.

Ticker CVAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,467,008
Market Cap $594M
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...

More about CVAC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

News

Stay updated on Squarepoint Ops LLC with notifications on news.

Account